학술논문
Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.
Document Type
article
Author
Sylvia Haas; Hugo Ten Cate; Gabriele Accetta; Pantep Angchaisuksiri; Jean-Pierre Bassand; A John Camm; Ramon Corbalan; Harald Darius; David A Fitzmaurice; Samuel Z Goldhaber; Shinya Goto; Barry Jacobson; Gloria Kayani; Lorenzo G Mantovani; Frank Misselwitz; Karen Pieper; Sebastian M Schellong; Janina Stepinska; Alexander G G Turpie; Martin van Eickels; Ajay K Kakkar; GARFIELD-AF Investigators
Source
PLoS ONE, Vol 11, Iss 10, p e0164076 (2016)
Subject
Language
English
ISSN
1932-6203
Abstract
Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend a target range of international normalised ratio (INR) of 2.0-3.0 for stroke prevention in atrial fibrillation (AF). We analysed the time in this therapeutic range (TTR) of VKA-treated patients with newly diagnosed AF in the ongoing, global, observational registry GARFIELD-AF. Taking TTR as a measure of the quality of patient management, we analysed its relationship with 1-year outcomes, including stroke/systemic embolism (SE), major bleeding, and all-cause mortality.TTR was calculated for 9934 patients using 136,082 INR measurements during 1-year follow-up. The mean TTR was 55.0%; values were similar for different VKAs. 5851 (58.9%) patients had TTR